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MUTATIONS OF p53 IN 
BARRETT'S ESOPHAGUS 
AND BARRETT'S CANCER: 
A PROSPECTIVE STUDY 
OF NINETY-EIGHT CASES 
We had previously identified p53 mutations in Barrett's esophagus and 
therefore began a multiinstitutional study to determine their significance as 
a marker for malignancy. Ninety-eight patients from four institutions were 
studied. Forty-eight patients (37 men and 11 women, mean age 56.2 years) 
had Barrett's esophagus with metaplasia or dysplasia but no evidence of 
malignancy at a mean follow-up of 2.2 years. Barrett's esophagus was 
classified as metaplasia with no evidence of dysplasia in 32 patients, as 
low-grade dysplasia in 13, and as high-grade dysplasia in three. The other 
50 patients (46 men and four women, mean age 60.2 years) had adenocar- 
cinoma arising in Barrett's esophagus. Tissues from normal stomach or 
esophagus, tumor, and Barrett's esophagus were obtained for deoxyribo- 
nucleic acid analysis by endoscopic biopsy from patients with Barrett's 
esophagus or cancer or during operations on some patients with Barrett's 
cancer. Exons 5 through 9 of the p53 gene were studied for mutations by 
single-strand conformational polymorphism analysis after polymerase 
chain reaction amplification. Mutations detected by single-strand confor- 
mational polymorphism analysis were confirmed by deoxyribonucleic acid 
sequencing. None of the tissue samples from patients with Barrett's 
esophagus alone and no dysplasia or low-grade dysplasia had any p53 
mutations, but one of the three patients with high-grade dysplasia and no 
evidence of invasive malignancy did have a p53 mutation. Of the 50 patients 
with Barrett's cancer, however, 23 (46%) had p53 mutations in Barrett's 
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epithelium, tumors, or both. Twenty of these patients had p53 mutations in 
the tumor only (n = 16) or in both tumor and Barrett's epithelium (n = 4), 
suggesting that the mutation plays a direct role in carcinogenesis. Muta- 
tions in Barrett's epithelium were found in one patient in the group without 
malignancy and in seven patients with cancer (one with no dysplasia, two 
with low-grade dysplasia, and five with high-grade dysplasia). In three 
patients with cancer, mutations occurred only in Barrett's epithelium, 
suggesting that such mutations may also be a marker for genomic 
instability. Mutations were predominantly found in exons 5, 7, and 8, and 
transitions from guanine to adenine were the most frequent changes. 
Mutations of p53 are clearly involved in the pathogenesis of Barrett's 
cancer for a subset of patients (46%), and the fact that we could detect 
mutations in premalignant Barrett's epithelium supports the hypothesis 
that p53 mutations may be a useful marker for patients at increased risk 
for development of invasive cancer. (J THORAC CARDIOVASC SURG 1996;111: 
323-33) 
B arrett's esophagus develops in approximately 10% 
to 12% of patients with chronic gastroesophageal 
reflux disease. 1 It is characterized by the replacement 
of the normal squamous epithelium of the esophagus 
with a metaplastic columnar epithelium. 2 
The potential for Barrett's epithelium to undergo 
malignant transformation is well recognized and 
accepted)' 4 In several prospective and retrospective 
studies, reported incidences of Barrett's cancer 
ranged from 1 in 56 patient-years to as low as 1 in 
441 patient-years, and there was an approximately 
30- to 40-fold increased risk for patients with Bar- 
rett's esophagus compared with the general popula- 
tion. 5 In addition, the incidence of adenocarcinomas 
in Barrett's esophagus and the gastric cardia in- 
creased more rapidly than that of any other cancer 
in the past two decades in the United States. 6 
Several studies upport he concept hat Barrett's 
adenocarcinoma does not occur de novo but arises 
as the result of tumor initiation and progression 
from benign metaplastic olumnar epithelium to 
varying degrees of dysplasia, carcinoma in situ, and 
invasive carcinoma. 4' 7-9 There is substantial evi- 
dence that Barrett's cancer is associated with a 
clonal evolution process as a result of acquired 
genomic instability through a progressive accu- 
mulation of genetic abnormalities, including the 
occurrence of single or multiple aneuploid cell 
populations 9-12 and chromosomal rearrangements.13 
Allelic losses involving chromosome 17p are fre- 
quently detected in Barrett's carcinoma a4 and pre- 
malignant Barrett's epithelium, as
The tumor-suppressor gene p53 is located on 
chromosome 17p, and wild-type p53 has been impli- 
cated in the control of the cell cycle, deoxyribonu- 
cleic acid (DNA) repair and synthesis, cell differen- 
tiation, genomic stability, and apoptosis, a6' 17 The 
p53 gene is the most commonly mutated gene in 
human cancers, Is and p53 mutations have also been 
detected in squamous cell carcinomas of the esoph- 
agus. 19'2° Casson and coworkers 21 first demon- 
strated p53 mutations in Barrett's cancer and pre- 
malignant Barrett's epithelium; these results were 
recently reconfirmed. 22Additional evidence for the 
involvement of p53 mutations in the neoplastic 
progression of Barrett's carcinoma comes from 
studies of p53 protein expression by means of mul- 
tiparameter flow cytometry and immunohistochem- 
istry.23,24 The purpose of this study was to deter- 
mine the significance of p53 mutation as a marker 
for adenocarcinoma arising in Barrett's epithelium. 
Patients and methods 
Study design and demographic data. Between Decem- 
ber 1991 and December 1994, patients with Barrett's 
metaplasia nd Barrett's carcinoma were recruited from 
the following four institutions: Technical University of 
Munich Medical Center (Munich, Germany), University 
of Western Ontario, London Regional Cancer Center and 
Victoria Hospital (London, Ontario, Canada), Tucson 
Veterans Administration Medical Center (Tucson, Ariz.), 
and The University of Texas M. D. Anderson Cancer 
Center, Houston, Texas. The exclusion criteria were pre- 
vious history of a malignant tumor or radiation therapy or 
chemotherapy before the tissue specimens to be analyzed 
were obtained. 
A total of 98 patients were evaluated, including 48 
patients with Barrett's esophagus only, without evidence 
of cancer (BE group), and 50 patients with Barrett's 
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cancer (BC group). There were 37 men and 11 women in 
the BE group; they had a median age of 56.2 years and a 
median length of Barrett's esophagus of 5.3 cm. The 
median follow-up was 2.2 years. The degree of dysplasia in 
metaplastic Barrett's epithelium was evaluated according 
to the criteria of Riddell, 25 simplified to include only three 
categories as suggested by Williamson and associates26: no 
evidence of dysplasia (NOD), low-grade dysplasia (LGD), 
and high-grade dysplasia (HGD). Thirty-two patients had 
NOD, 13 had LGD, and three had HGD. 
Barrett's cancer was defined as adenocarcinoma origi- 
nating above the gastroesophageal junction in association 
with characteristic columnar mucosa. At least 75% of the 
tumor had to occupy the tubular esophagusF The BC 
group included 46 men and four women, with a median 
age of 60.3 years. Forty-eight of the 50 patients underwent 
surgical resection, and two of the 50 patients received 
primary radiochemotherapy for palliation. Tumor staging 
was performed according to the International Union 
Against Cancer (IUCC) TNM classification (4th ed., 2nd 
revision, 1992): 16 patients had stage I tumors, 15 had 
stage II tumors, 16 had stage III tumors, and three had 
stage IV tumors. The primary tumors were graded his- 
topathologically as well-differentiated (G1, nine patients), 
moderately differentiated (G2, 18 patients), poorly differ- 
entiated (G3, 19 patients), and undifferentiated (G4, four 
patients). 
Tissue acquisition. Tissue for DNA analysis was ob- 
tained from patients with Barrett's esophagus (BE group) 
by endoscopic biopsy. At least two separate areas were 
sampled routinely, one within 1 to 2 cm above the cardia 
and one approximately 1 to 2 cm distal to the border 
between squamous epithelium and Barrett's epithelium. 
In patients with Barrett's cancer (BC group), tissue was 
obtained by endoscopic biopsy or at operation. Tissues 
from the following locations were analyzed: tumor, peri- 
tumoral Barrett's epithelium, and Barrett's epithelium as 
far from the tumor as possible. If there was only a small 
area of tumor-free Barrett's epithelium (as in some pT3 
and pT4 tumors), only peritumoral Barrett's epithelium 
was analyzed. For both groups, normal tissues were taken 
from the gastric fundus and squamous epithelium of the 
esophagus. All tissue specimens were immediately frozen 
in liquid nitrogen or fixed in formaldehyde. Conventional 
histologic analysis of all tissue specimens analyzed for p53 
mutations was performed by gastrointestinal pathologists 
(K. B. for the German subjects and K. R. C. and M. T. for 
the North American subjects). This study was approved by 
the internal review boards of all involved institutions. 
DNA amplification, polymerase chain reaction (PCR) 
single-strand conformation polymorphism (SSCP) anal- 
ysis, and DNA sequencing. DNA was isolated with a 
DNA extraction kit (Stratagene Inc., La Jolla, Calif.). 
Exons 5 through 9of the p53 gene were analyzed because 
more than 90% of mutations in the p53 gene occur in this 
evolutionarily conserved part of the gene. 2s For PCR 
amplification, oligonucleotide primer pairs for exons 5 
through 9 derived from p53 sequences deposited in Gen- 
Bank by Peter Clumakov (accession o. X54156) were 
chosen as reported. 29 A 0.1/xg portion of DNA was added 
to a 25 /xl reaction mixture containing 1 t~mol/L of each 
primer (MWG Biotech, Ebersberg, Germany), or synthe- 
sized with a DNA synthesizer (model 392; Applied Bio- 
systems, Foster City, Calif.), 1.5 mmol/L magnesium chlo- 
ride, 10 mmol/L tris-hydroxymethyl-amino methane 
hydrochloride (pH 8.3), 50 mmol/L potassium chloride, 
and 0.001% gelatin (all reagents from Sigma Chemical 
Co., Munich, Germany, or St. Louis, Mo.), 200 txmol/L 
each deoxyadenosine triphosphate, deoxycytidine tri- 
phosphate (dCTP), deoxyguanosine triphosphate, dCTP 
(Pharmacia, Stockholm, Sweden) for nonradioactive 
SSCP or a mixture of 100/xmol/L dCTP and c~-32p-dCTP 
(Amersham Corp., Arlington Heights, Ill.) for radioactive 
SSCP, and 0.625 U Taq polymerase (Pharmacia). The 
samples were amplified with a Perkin Elmer Cetus Ther- 
mocycler 480 (Perkin-Elmer Corp., Norwalk, Conn.) un- 
der the following conditions: an initial denaturation step 
at 94 ° C for 5 minutes and 35 cycles of denaturation at
94 ° C for 1 minute, annealing at 58 ° C for 1 minute, and 
elongation at 72 ° C for i minute. The PCR products were 
checked on a 3% GeneAmp agarose gel (Perkin-Elmer). 
Two types of SSCP analysis were performed: a nonradio- 
active form that used the Pharmacia PCR-Fragment Anal- 
ysis Kit, with 15% polyacrylamide gel electrophoresis 
horizontal at 15°C and silver staining according to the 
manufacturer's recommendations, and a radioactive form 
with vertical 12% polyacrylamide gel electrophoresis at 
4 ° C, with 0.5x Tris-borate-ethylenediaminetetraacetic 
acid running buffer as reported previously) ° SSCP 
analysis was performed at least twice by each proce- 
dure, and DNA sequencing was performed on samples 
that showed an electrophoretic mobility shift. Three 
samples that had unequivocal mobility shifts could not 
be sequenced because not enough DNA was available. 
Direct sequencing of both strands of the PCR products 
was performed after amplification with paired biotiny- 
lated and nonbiotinylated primers (MWG Biotech) and 
strand separation with strepavidin-coated magnetic 
beads (Dynal Inc., Hamburg, Germany) by solid-phase 
single-strand sequencing with the Sequenase version 2.0 
Sequencing Kit (United States Biochemical, Cleveland, 
Ohio) according to the manufacturer's ecommenda- 
tions. For samples with exon 5 mobility shifts and 
samples found to have mutation by SSCP but not by 
direct DNA sequencing, subcloning and double-strand 
DNA sequencing were performed with the TA-Cloning 
Kit (InVitrogen, San Diego, Calif.). 
Results 
Prevalence of p53 mutations in BE and BC 
groups. SSCP analysis and DNA sequencing re- 
vealed p53 mutations in one of 48 patients in the BE 
group and 23 of 50 patients in the BC group. 
Representative xamples of SSCP analyses and 
DNA sequencing are shown in Figs. 1 and 2. 
In a patient in the BE group, a p53 mutation in 
exon 5 was present in an area of HGD, but two 
additional areas with LGD, had no mutations. In the 
BC group, 16 patients had p53 mutations in their 
tumors but not in peritumoral Barrett's epithelium 
or distant Barrett's epithelium. Four patients had 
3 2 6 Schneider et aL 
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Fig. 1. Lefipanel, PCR SSCP analysis of exon 8 in a patient with Barrett's cancer (patient 28). Specimens 
were analyzed from the tumor (T1), two separate loci of Barrett's epithelium with LGD (BI) and NOD 
(t72), and histologically normal esophageal squamous epithelium (E). An electrophoretic mobility shift 
(aberrant bands) is clearly detected in T1 (arrows). Right panel, DNA sequencing of tumor (T) and 
epithelium (E) showed a guanine to adenine transition mutation (arrow) in codon (CGG --+ CAG) that 
resulted in an amino acid change (glycine --+ arginine). 
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Fig. 2. Leftpanel, PCR SSCP analysis of exon 7 in a patient with Barrett's cancer (patient 2). Specimens 
were analyzed from the tumor (T), Barrett's epithelium with no evidence of dysplasia (t?), and histologically 
normal squamous esophageal epithelium (E). An electrophoretic mobility shift was detected in B (arrow). 
Right panel, DNA sequencing of B and E revealed a one base pair guanine deletion (arrow) in codon 237 
(GTG ~ TG), which resulted in a frameshift. 
mutations both in their tumors and in Barrett's 
epithelium. Two of the four had identical mutations 
in their tumors and peritumoral Barrett's epithelium 
with HGD.  The mutations were located in exon 8 in 
both patients and were a missense mutation in 
codon 278 (CCT ~ CTT; cytosine to thymine 
transition) and a frameshift mutation in codons 
316-317 (CCCCAG ~ CCCCCAG,  cytosine inser- 
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Table I. Characteristics of patients with p53 mutations in Barrett's cancer (BC group) 
Histology of Mutation in 
Patient UICC Barrett's Mutation Barrett's 
no. Age Sex stage Grade epithelium in tumor epithelium Group 
2 65 M III G3 LGD Exon 7/DEL NEG I 
4 63 M III G3 LGD Exon 5/TS NEG I 
5 56 M III G2 HGD Exon 7/TS NEG I 
7 57 M III G3 LGD Exon 7/TS NEG I 
10 56 M II G2 NOD Exon 5/TS NEG I 
12 62 M II G4 NOD NEG Exon 7/DEL IV 
14 83 M II G3 NOD Exon 5/TS NEG I 
18 60 M III G3 HGD Exon 5/DEL NEG I 
20 70 M I G2 LGD NEG Exon 7/TS IV 
22 49 M I G1 LGD Exon 5/DEL NEG I 
27 61 M I G2 LGD(+)  Exon 5/TS NEG I 
28 59 M I G1 HGD Exon 8/TS Exon 8/TS II 
30 72 F III G3 LGD(+)  Intron 4/exon 5/TS Exon 9/ND III 
31 65 M IV G3 HGD Exon 8/TV Exon 7/TS III 
32 58 M II G3 HGD NEG Exon 5/DEL IV 
34 54 M III G2 HGD Exon 8/TS NEG I 
36 58 M I G2 LGD Exon 6/TS NEG I 
38 71 M I G1 NOD Exon 6/ND NEG I 
39 58 M ! G1 NOD Exon 7/TS NEG I 
41 52 M III G3 NOD Exon 8/TS NEG I 
44 78 M III G3 LGD Exon 6/DEL NEG II 
46 68 M III G1 LGD Exon 8/INS Exon 8/INS II 
49 73 M I G3 HGD Exon 7/ND NEG I 
Group classification based on the presence or absence of p53 mutations intumor or Barrett's epithelium:/, Mutation in tumor; II, identical mutation i  tumor 
and Barrett's epithelium; III, discordant mutation in tumor and Barrett's epithelium;/V, mutation only in Barrett's epithelium. DEL, deletion; NEG, no 
mutations; TS, transition; TV, transversion; ND, not determined; INS, insertion. 
tion). The other two patients had different muta- 
tions in the tumor and Barrett's epithelium. One 
patient had a missense mutation in codon 275 of 
exon 8 (TGT ---> TTT; guanine to thymine transver- 
sion) in the tumor and a missense mutation in codon 
248 of exon 7 (CGG --+ TGG; cytosine to thymine 
transition) in peritumoral Barrett's epithelium with 
HGD. The other patient had a splice-site mutation 
(junction of intron 4 and exon 5) and a mutation in 
exon 9 in Barrett's epithelium distant from the 
tumor with LGD. 
Three patients had mutations in areas of Barrett's 
epithelium but the corresponding tumors did not 
show p53 mutation. In two patients, the Barrett's 
epithelium samples with the p53 mutations were 
from peritumoral areas with NOD (exon 7 muta- 
tion) and HGD (exon 5 mutation). In one patient, 
Barrett's epithelium with LGD distant from the 
tumor had an exon 7 mutation. 
Relationship of p53 mutations to tumor stage, 
grading, and dysplasia in Barrett's epithelium. 
Mutations of p53 occurred in tumors of all tumor 
stages (Table I). The presence of p53 mutations in 
seven IUCC stage I cancers indicates that the mu- 
tational event occurred relatively early in tumor 
development. In two patients, peritumoral Barrett's 
epithelium with HGD and the tumor had the same 
mutation; one tumor was classified as stage I, dem- 
onstrating that the mutation preceded tumor devel- 
opment. This is further substantiated by the pres- 
ence of a p53 mutation in a BE-group patient with 
HGD without evidence of invasive carcinoma. Mu- 
tations were observed in well, moderately, and 
poorly differentiated tumors but not in undifferen- 
tiated tumors; however, there were few G4 tumors 
(four) in our series (50). 
One patient with NOD, two with LGD, and five 
with HGD had p53 mutations. Although mutations 
were observed more frequently in areas of the 
esophagus with HGD, they were also observed 
before the development of HGD, 
Location and type of p53 mutations. A total of 27 
specimens from the BE and BC groups had p53 
mutations. The location and types of mutations that 
occurred are summarized in Table II. Mutations 
were most frequently present in exon 5 (35.7%), 
followed by exons 7 (28.6%) and 8 (25%). Muta- 
tions in exons 6 and 9 appeared to occur rarely. 
Twenty-four of 27 unequivocal mutations, as deter- 
mined by SSCP could be sequenced and character- 
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Table II. Locations and types of p53 mutations 
Exon Exon Exon Exon Exon 
Mutation 5 6 7 8 9 n % 
Transition 4 1 5 4 0 14 50.0 
Transversion 0 0 0 1 0 1 3.6 
Deletion 4 0 2 0 0 6 21.4 
Insertion 0 0 0 2 0 2 7.1 
Splice site 1 1 0 0 0 2 7.1 
Not analyzed 1 0 1 0 1 3 10.7 
n 10 2 8 7 1 28 100 
% 35.7 7.1 28.6 25 3.6 100 
ized. The most frequent type of mutation in the p53 
gene was a transition (14 of 24), which led in all 
cases to a change in the amino-acid sequence. 
Among these transition mutations, guanine to ade- 
nine transitions were most common (n = 8), fol- 
lowed by cytosine to thymine (n = 4) and adenine to 
guanine (n = 2) transitions. Four transitions oc- 
curred at cytosine-guanine dinucleotides. Deletions 
were the next most common mutations (six of 24); 
four were i base pair, one was 2 base pairs, and one 
was 11 base pairs; all caused frameshifts. Insertions 
and transversions were rare, observed in only one 
patient each. 
Discussion 
Casson and coworkers 21first reported p53 muta- 
tions in Barrett's epithelium and carcinomas; more 
recently, Neshat and associates 22 found p53 muta- 
tions in seven of 12 patients with Barrett's cancer. 
The results of our analysis of a larger sample were 
consistent with the results of these studies, which 
indicated that p53 mutations Occurred in approxi- 
mately 46% to 56% of patients with Barrett's can- 
cer. These patients could be classified into five 
groups on the basis of the presence and absence of 
p53 mutations: group I (32%), p53 mutation 0nly in 
the tumor; group II (4%), concordant p53 mutations 
in the tumor and Barrett's epithelium; group III 
(4%), discordant p53 mutations in the tumor and 
Barrett's epithelium; group IV (6%), p53 mutation 
only in Barrett's epithelium; and group V (54%), no 
p53 mutation in either the tumor or Barrett's epi- 
thelium. 
The existence of groups I and II is consistent with 
a process of clonal evolution, a mechanism proposed 
by Nowell. 3~ Using flow-cytometry in a prospective 
study of patients with Barrett's esophagus, Reid and 
colleagues 9 reported that progression to adenocar- 
cinoma is associated with a clonal evolution process. 
This process included the development of single or 
multiple aneuploid cell populations 11 and allelic 
losses on chromosomes 17p and 5@ 2 involving the 
p53, APC, MCC, and Rb gene loci. 32 The existence 
of group II provides evidence that p53 mutation 
probably occurs before the development of invasive 
carcinoma in premalignant Barrett's epithelium, as 
has been reported for other aerodigestive tract 
cancers.16, 18, 33, 34 
Discordant mutations in tumor and premalignant 
epithelium (group III) have already been reported 
in squamous cell carcinomas of the esophagus, 34 
suggesting that multifocal neoplasms can arise in 
both esophageal squamous cell carcinomas and Bar- 
rett's associated adenocarcinomas. The same con- 
clusion could apply to group IV, patients with p53 
mutation in Barrett's epithelium but not the tumor. 
Multiple areas of different degrees of dysplasia can 
exist in the same patient with Barrett's esophagus or 
Barrett's cancer and can include the occurrence of 
multiple aneuploid cell popuiations. 9' 11, 22 Progres- 
sion to cancer in patients with Barrett's esophagus 
has been shown to be associated with increased 
genomic instability, l° It is therefore likely that a clone 
without p53 mutation but with a selective growth 
advantage formed a malignant tumor and that an area 
of Barretfs epithelium with a p53 mutation was at an 
earlier stage of tumorigenesis. This histologic pattern 
could also be explained by the field Cancerization 
theory, 3s which would imply that the metaplastic Bar- 
rett's epithelium of these patients would be at in- 
creased risk for cancer development. 
Demonstration f p53 mutations in one of three 
patients in the BE group with HGD, in premalig- 
nant Barrett's epithelium in patients with Barrett's 
carcinoma, nd in early Barrett's carcinomas (UICC 
stage I) is consistent with previous reports TM 22 that 
p53 mutations must occur at an early stage of tumor 
development and may precede the formation of 
microinvasive tumors. Mutations of p53, however, 
were not detected in 47 patients of the BE group 
with NOD or LGD. This does not contradict our 
hypothesis, because the median follow-up period 
was 2.2 years and the incidence of Barrett's cancer is 
approximately one in 56 to one in 441 patient-years. 5 
Overexpression f p53 protein was first shown in 
a subset of Barrett's carcinomas. TM Ramel and co- 
workers 23 detected p53 protein overexpression i  
Barrett's metaplasia n one of 21 patients (5%) with 
NOD, two of 13 with LGD (15%), five of 11 with 
HGD (45%), and eight of 15 with Barrett's carci- 
noma (53%). Younes and colleagues 24found posi- 
tive immunostaining forp53 in no cases with NOD, 
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9% of cases with LGD, 55% with HGD, and 87% 
with adenocarcinoma. Rice and associates 36 re- 
ported that no p53 immunoreactivity was seen in 
Barrett's metaplasia with NOD or LGD and that 
positive immunostaining occurred in 69% of speci- 
mens with HGD, 67% with intramucosal cancer, 
and 40% with submucosal cancer. A study by Jones 
and colleagues 37showed significant p53 immunore- 
activity in Barrett's esophagus specimens with NOD 
(10%), LGD (60%), and HGD (100%); however, 
adenocarcinomas in Barrett's esophagus howed 
significant p53 expression i only 70% of specimens. 
The disparate results of these studies are difficult to 
interpret and could reflect variations in observer 
interpretation and the use of different antibodies 
and staining procedures. In addition, p53 protein is 
expressed at very low levels in most cell types, and 
wild-type p53 expression might be increased by 
mechanisms other than gene mutations. 17The cor- 
relation between increased immunoreactivity and 
the presence of mutations i  imperfect. For example, 
frameshift or chain-terminating (nonsense) muta- 
tions and deletions may not be detected, because the 
resultant protein is absent, truncated, or unstable. 16
The wild-type p53 protein may spontaneously 
change its conformation i cancer cells and assume 
a mutant conformation. 3s'39 This conformational 
change would be detected by monoclonal ntibodies 
that recognize the mutant conformation. The use of 
certain antibodies could overestimate the incidence 
of p53 mutations on the basis of the level of p53 
expression. 
Our results indicate that it is likely that the vast 
majority of the positive immunostaining seen in 
Barrett's metaplasia with NOD or LGD does not 
reflect the presence of p53 mutation. We did not 
detect p53 mutations in any of the 32 patients with 
NOD or the 13 patients with LGD in the BE group. 
Allelic deletions of chromosome 17p have been 
reported in Barrett's carcinomas and Barrett's dys- 
plasia.14, 15 Although allelic deletions are frequently 
associated with p53 mutations in the remaining 
allele, such mutations (which are required to inac- 
tivate the tumor-suppressor-gene) ne d to be dem- 
onstrated to conclude that p53 tumor-suppressor 
function is absent. 17 Empirically, loss of 17p includes 
loss of a normal p53 gene; however, another cancer- 
related gene on 17p could also be lost, so the effect 
of the loss of p53 function is therefore much more 
precisely assessed by direct analysis of the p53 
gene. aa 
In our study, p53 mutations in premalignant Bar- 
rett's epithelium and Barrett's cancer were more 
frequent in exons 5, 7, and 8 than in exons 6 and 9. 
Mutational hot spots for p53 have been reported for 
hepatocellular carcinoma in codon 2494o and for 
colon carcinomas in codons 175, 248, and 273.18 Six 
of 24 p53 mutations (25%) that could be analyzed by 
DNA sequencing were in codons 248 and 273. In 
addition, most of the mutations were transitions of a 
guanine-cytosine to an adenosine-thymine base pair, 
which also frequently occur in colon 18 and gastric 
carcinomas. 4a Squamous cell carcinomas of the 
esophagus and lung cancers how a predominance 
of transversion mutations in p53,19' 2o however, and 
both cancers are tobacco-related diseases, as This 
observation suggests that the two types of esopha- 
geal cancer arise by different mechanisms; transver- 
sions are associated with exposure to exogenous 
carcinogens (e.g., tobacco smoke) and transitions 
may involve spontaneous deamination of 5- 
methylcytosine at cytosine-guanine dinucleotides. 42 
In addition, oxygen radicals enhance the rate of 
deamination of deoxynucleotides, and chronic in- 
flammation and nitric oxide produced by nitric oxide 
synthase may contribute to the high frequency of 
transition mutations such as of a guanine-cytosine to 
an adenosine-thymine base pair. 43 It is important to 
determine whether inducible nitric oxide synthase is
constitutively overexpressed in Barrett's metaplasia 
as it is in ulcerative colitis, 44' 45 a disease with a high 
risk for the development of colorectal cancer. 46 
In summary, our study shows that p53 gene 
mutations were involved in the development of 
Barrett's cancer in some patients. Although it seems 
likely that p53 mutations occur in patients with 
Barrett's esophagus before the development of in- 
vasive cancer in Barrett's epithelium with LGD or 
even NOD, prospective studies of well-defined co- 
horts of patients with Barrett's esophagus with ex- 
tended follow-up are needed to confirm this hypoth- 
esis. One of us (P. M. S.) is proceeding with this 
study. In the absence of such data, it is reasonable to
consider p53 as a marker gene for the development 
of adenocarcinoma in Barrett's esophagus. We be- 
lieve that the presence of a documented p53 muta- 
tion in Barrett's metaplasia or dysplasia indicates a
high risk for the development or presence of ade- 
nocarcinoma. The patient should therefore undergo 
esophagoscopy at 3-month intervals, with appropri- 
ate biopsy samples obtained. If a p53 mutation is 
documented in HGD, esophagectomy should be 
considered because of the high probability of inva- 
sive carcinoma. 
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Discuss ion 
Dr. Thomas W. Rice (Cleveland, Ohio). I agree that p53 
should be considered a marker gene for the development 
of adenocarcinoma in Barrett's esophagus. This finding 
may be of importance in the laboratory study of the 
metaplasia, dysplasia, carcinoma sequence. To be clini- 
cally useful, however, this mutation should occur in all 
patients and should be detectable before the development 
of invasive carcinoma. 
From your work and that of others, it appears that only 
half of the patients with Barrett's carcinoma have a 
mutation of this gene. There is also some disagreement as
to when this mutation occurs. 
Our experience suggests that this mutation occurs dur- 
ing the transition to HGD. In this study, HGD was 
observed in only three of 48 patients without Barrett's 
carcinoma, and one p53 mutation was detected. My first 
question concerns the sampling of this group, which 
consisted of two biopsies, one performed 1 to 2 cm above 
the cardia and one performed 1 to 2 cm below the 
squamocolumnar junction. Could you have underesti- 
mated the occurrence of HGD and the p53 mutation in 
this dysplastic epithelium by not using the standard Bar- 
rett's surveillance techniques of four quadrant biopsies 
every 2 cm along the Barrett's egment? 
In the BC group, of the 23 patients with p53 mutations 
only five had this mutation detected in areas of HGD. 
Sixty-eight percent of these carcinomas were stage II or 
greater. My second question concerns a sampling of this 
group, which consisted of sampling only of three areas, the 
tumor, the peritumor Barrett's epithelium, and distant 
Barrett's epithelium. Could you have underestimated the 
occurrence of HGD and p53 mutations by this sampling 
protocol and by the invasion and destruction of the 
dysplastic forerunner of these late-stage carcinomas? 
My third question concerns the clinical application of 
this information. What are your current recommendations 
about the search for p53 mutation in patients with Bar- 
rett's esophagus, and how would you manage the treat- 
ment of a patient with a p53 mutation and no evidence of 
invasive carcinoma? 
Finally, Barrett's carcinoma is a disease of middle-aged 
and elderly white men. There were 15 women in your 
study, four with Barrett's carcinoma. Did the frequency 
and type of mutations in female patients differ from those 
seen in male patients? 
Dr. Schneider. Concerning your first question, for the 
conventional studies we did four quarter biopsies as 
suggested by Reid. It is impossible to examine very single 
sample, and you may be right that we may therefore have 
underestimated the occurrence of p53 mutations. I sug- 
gest in the future the additional use of esophageal brush- 
ings, because we have done experiments hat showed that 
one mutant cell in a million normal cells can be detected. 
The problem of p53 mutations in peritumor Barrett's 
epithelium with HGD is complicated by the fact that if a 
tumor grows, peritumor Barrett's epithelium ight be far 
away from the tumor center, especially with T2 or more 
advanced tumors. In two T1 categories, we have seen the 
identical mutations when there were mucosal-type carci- 
nomas. You may also be right that we underestimated, but 
I think that there is just no way to determine this, 
especially for every tumor that is more than a mucosal 
cancer. 
Dr. Rice. What is your recommendation for the sam- 
pling of Barrett's esophagus, and how would you manage 
the case of a patient with a p53 mutation and no invasive 
carcinoma? 
Dr. Schneider. I commented on this. I think it is not 
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possible to analyze four quarter biopsy samples molecu- 
larly. That is why I would consider using brushings. 
How would I manage a patient with a p53 mutation? 
We would follow him or her up every 3 months. At my 
university hospital, we had one patient who underwent 
resection with HGD. This was a very young patient; he 
was 45 years old. He had repeated positive results on two 
occasional biopsies, and we decided to perform resection. 
This is a very unusual situation. We otherwise recommend 
repeated biopsies every 3 months. If one shows invasive 
cancer, we proceed with the resection. At the M. D. 
Anderson Cancer Center, however, which participated in
our study, resection is recommended for Barrett's esoph- 
agus with severe dysplasia because of the high incidence of 
invasive cancers found in resected specimens. 
Dr. Rice. Were there differences in the mutations 
between the male and female patients? 
Dr. Schneider. We had so few female patients in the 
study that we cannot conclude anything. 
Dr. Valerie W. Ruseh (New York, N.Y.). At first glance, 
it may not appear that an analysis of p53 mutations in 
cancers related to Barrett's esophagus i  clinically rele- 
vant. However, this type of study represents part of the 
future management of our patients. 
During the last 20 years, we have meticulously defined 
the natural history of the common thoracic malignancies 
and have improved the surgical management of those 
malignancies. Despite this, there has been little improve- 
ment in overall survival for patients with lung or esopha- 
geal cancer. We need to understand the fundamental 
biologic changes associated with tumor initiation and 
progression to develop effective methods of early detec- 
tion and novel treatment strategies. This carefully per- 
formed study is one step toward gaining that understand- 
ing. 
The protein expression of the p53 gene can be altered 
either through gene mutation or by inactivation of a 
structurally normal p53 gene. The ubiquitous presence of 
p53 abnormalities in solid tumors uggests that it is part of 
an important pathway common to the development and 
growth of most cancers. Indeed, p53 is a multipotential 
gene. It is thought o modulate cell-cycle dynamics and to 
be a regulator of apoptosis, programmed cell death. 
Through its effects on apoptosis, it appears to influence 
responsiveness to both chemotherapy and radiation. 
Previous work, both by you and by other investigators, 
examined p53 abnormalities by chromosomal analysis, 
flow cytometry, and immunohistochemistry, and sug- 
gested that altered p53 expression is frequent in cancers 
related to Barrett's esophagus. This study extends previ- 
ous work in a precise and quantitative manner by directly 
examining ene mutations. You are to be commended for 
performing this biologic study across several institutions, 
something often easier said than done. 
The findings of this study are similar to those recently 
reported with respect to preneoplastic bronchial epithelial 
lesions, namely that p53 abnormalities are seen in HGD, 
cancer in situ, and invasive cancers, but rarely in metapla- 
sia or LGD. With regards to Barrett's cancers, an impor- 
tant clinical question for which we need a biologic answer 
is which molecular genetic abnormalities allow us to 
identify patients at risk for progression through the se- 
quence of metaplasia to dysplasia, and from varying 
grades of dysplasia on to invasive cancer. 
I have a couple of questions. Have you started to do 
longitudinal follow-up of patients with dysplasia to con- 
firm whether p53 abnormalities uniformly predict progres- 
sion of dysplasia to cancer in situ or invasive cancer? In 
lung cancer, it has been shown that some tumors exhibit 
abnormal p53 expression by immunohistochemistry with- 
out having p53 gene mutations. This might explain the 
discrepancy between your results and previous immuno- 
histochemical studies suggesting that p53 expression is 
abnormal even in LGD. Do you plan to do immunohisto- 
chemistry on your specimens to determine whether there 
is discordance between gene mutation and protein expres- 
sion? 
Dr. Schneider. To answer your first question, all of the 
patients are in a longitudinal study. Patients with NOD 
are evaluated with four quarter biopsies every 2 years, 
patients with LGD are evaluated once a year, and patients 
with HGD are evaluated, including p53 analysis, every 3 
months. We have reevaluated approximately one third of 
those patients, and the results remain the same. 
In reply to your second question concerning immuno- 
histochemistry, one of the problems with immunohisto- 
chemistry is that neither lack of expression of p53 nor 
overexpression is absolutely associated with the process of 
malignant transformation. If there is a deletion mutation, 
which occurred in approximately 30% of our specimens, 
you will not be able to detect it by immunohistochemistry. 
You will have false-negative results, because the cell 
cannot make the protein, even though p53 is absent and 
cannot control the cell cycle. In the case of overexpres- 
sion, you have approximately 10% false-positive r sults. 
The p53 analysis may be good if you have the immuno- 
histochemistry in addition to a molecular analysis, but if 
you have the immunohistochemistry alone, you cannot 
really conclude a lot from those data. I would be very 
critical of using only immunohistochemistry. I have done 
immunohistochemistry for my set of patients, which con- 
stitute about 50% of the patients presented. We have 
concordance of the two methods in approximately 70% of 
cases, and in 30% we have mainly false-negative and very 
few false-positive r sults. 
Dr. Victor F. Trastek (Rochester, Minn.). I think the key 
question is when to perform resection on these patients. 
We all appreciate that there is an opportunity to intervene 
in a carcinogenic process o that we can help the patient. 
It appears that we are all trying to figure out the exact ime 
to proceed with resection. It is often as though the patient 
sits there with a bomb with a burning fuse; we just don't 
know how long the fuse is. We hope that techniques like 
this will help us to guess which patients have short fuses. 
Therefore, I ask you, what are your indications for 
resection when you have a patient with HGD? I think you 
indicated that you would wait 3 months and resample, 
waiting for invasive carcinoma to be found. What evidence 
do you have that this is a successful technique in treating 
patients with HGD? As you know, a percentage of these 
patients will have occult invasive cancer. I think many of 
us feel that once the cancer is invasive the chance of 
lymph node disease goes up and the cat is out of the bag, 
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or, stated differently, the bomb has exploded and it is 
probably too late. 
Dr. Schneider. This is a very critical question. At the 
Technical University of Munich, we follow the policy of 
Reid's group. You remember that in the article in Gas- 
troenterology approximately 1 or 2 years ago, Reid's group 
showed that they were quite good in following up patients 
with HGD with multiple biopsies and determining the 
time point when to resect. They recommended follow-up 
every 3 months from their experience. For my hospital, I 
can say that we are conservative in this respect. We resect 
when we have a biopsy specimen with invasive cancer, 
because there is a significant mortality rate associated with 
this procedure. 
Dr. Arthur N. Thomas (San Francisco, Calif.). I am 
hesitant o bring this up, but in the last 25 years or so it 
seems to me that from about 5% of the patients that we 
treat with carcinoma of the esophagus to, in my practice 
now, nearly 50%, have cancer elated to Barrett's esoph- 
agus. I think this has come about by the unfortunate or 
unrelated events of treatment of reflux gastroesophagitis 
at a time when we are able to effectively prevent gastro- 
esophagitis and reflux. Particularly more recently, with 
laparoscopic techniques, we are not seeing these patients 
because they are undergoing dilation, reendoscopy, and 
follow-up by the gastroenterologist for 10 or 15 years in 
some cases. 
I recently had a case where exactly that was the 
situation. The patient had carcinoma associated with 
Barrett's esophagus that involved practically the entire 
esophagus, at 19 cm from the incisors. I just wonder about 
a third arm of this type of study, earlier treatment and 
prevention of Barrett's esophagus, and whether you have 
any patients that had the p53 changes that had undergone 
hiatus hernia repair where these changes regressed. What 
are your thoughts in this general area? 
Dr. Schneider. We had only one patient with a muta- 
tion, and this patient underwent resection. As I said, this 
is a unique situation. 
On the other hand, if I understand your question 
correctly, you imply that the reflux is causing the disease, 
or the reflux is causing the inflammation and the inflam- 
mation is causing the disease. There must be something 
more to it, however, because you know from the longitu- 
dinal studies, incidence studies of Barrett's cancer, that 
only a minor percentage of patients eventually acquire 
Barrett's cancer. I think it is still really unknown what the 
inducing mechanism is. 
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